Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction

• Published in: Archives of medical research Vol. 49; no. 8; pp. 620 - 629
• Main Authors: García-Méndez, Rosalba C., Almeida-Gutierrez, Eduardo, Serrano-Cuevas, Leonor, Sánchez-Díaz, Jesús Salvador, Rosas-Peralta, Martín, Ortega-Ramirez, Jose Alberto, Palomo-Villada, Jose Antonio, Isordia-Salas, Irma, Alonso-Bravo, Rosa Marisol, Borrayo-Sanchez, Gabriela
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2018
• Subjects: Acute ST elevation myocardial infarction; Biomarkers; No Reflow; Percutaneous coronary intervention; Reperfusion injury; Statins; No Reflow; Biomarkers; Percutaneous coronary intervention; Acute ST elevation myocardial infarction; Reperfusion injury; Statins
• ISSN: 0188-4409; 1873-5487
• DOI: 10.1016/j.arcmed.2018.10.006

No reflow defined as an altered myocardial reperfusion and failure at microvascular level is a frequent complication in acute myocardial infarction that attenuates beneficial effect of reperfusion therapy leading to poor outcomes. There is not enough evidence to support that previous use of statins improves coronary flow in patients undergoing primary percutaneous coronary intervention (PCI). To determine if a loading dose of 80 mg of atorvastatin before primary angioplasty reduces the frequency of no reflow, hs-CRP, IL6 intracoronary levels, and major combined cardiovascular events at 30 d. In this controlled clinical trial, we randomly assigned 103 adult patients within the 12 h of acute ST-elevation myocardial infarction (STEMI) to receive 80 mg of atorvastatin additional to standard treatment (AST) before performing primary PCI versus standard treatment (ST) alone. The primary outcomes were the occurrence of no reflow and high sensitivity C-reactive protein (hs-CRP) and interleukin 6 levels and secondary outcomes were major adverse cardiovascular events at 30 d. 103 patients were analyzed, 49 (48%) received AST, 54 (52%) ST. Frequency of no reflow among groups was 27 vs. 63% respectively, p ≤0.0001. hs-CRP level was 2.69 mg/dL for AST vs. 2.2 mg/dL in ST, meanwhile IL-6 levels were 5.2 pg/mL vs. 6.35 pg/mL respectively, p = ns. Cox regression model demonstrated that the treatment assigned is an independent predictor for no reflow occurrence (HR 0.34 95%, CI 0.18–0.61, p ≤0.001). The administration of a loading dose of 80 mg atorvastatin before primary PCI is an effective strategy for prevention of no reflow improving also clinical outcomes and free survival rate for the presentation of major adverse cardiovascular events at 30 d.